So far, China has made no official public threat about weaponizing its dominant position in this segment of the ...

Hedge funds revealed their top investment ideas, ranging from Chinese self-driving taxis, an Indian drug retailer, to a ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed ...

India's pharma sector is at a turning point as the government seeks to strengthen local manufacturing through an upgraded ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

The president’s proposed 25 percent tariffs on pharmaceutical imports will be catastrophic. There are other options to bring ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract ...

US President Donald Trump on May 23 threatened to impose a 50 percent tariff on all imports from the European Union.

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance generating revenues with ensuring that a new medicine reaches the largest possible ...